PMP22 Gene–Associated Neuropathies: Phenotypic Spectrum in a Cohort from India

• Published in: Journal of molecular neuroscience 2020-05, Vol.70 (5), p.778-789
• Main Authors: Nagappa, Madhu, Sharma, Shivani, Govindaraj, Periyasamy, Chickabasaviah, Yasha T., Siram, Ramesh, Shroti, Akhilesh, Debnath, Monojit, Sinha, Sanjib, Bindu, Parayil S., Taly, Arun B.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age; Age Factors; Aged; Biomedical and Life Sciences; Biomedicine; Cell Biology; Child; Copy number; Correlation analysis; Cranial nerves; Demyelinating Diseases - epidemiology; Demyelinating Diseases - genetics; Demyelinating Diseases - pathology; Demyelination; Etiology; Female; Gene Duplication; Genetic diversity; Genetic variance; Genetics; Genotypes; Hearing loss; Heterogeneity; Humans; India; Male; Median nerve; Middle Aged; Missense mutation; Muscles; Mutation; Myelin Proteins - genetics; Nerve conduction; Neurochemistry; Neurology; Neuropathy; Neurosciences; Ophthalmoplegia; Peripheral myelin protein 22; Peripheral Nervous System Diseases - epidemiology; Peripheral Nervous System Diseases - genetics; Peripheral Nervous System Diseases - pathology; Peroneal nerve; Phenotype; Phenotypes; Polymorphism, Genetic; Proteomics; Reflexes; Reproduction (copying); Sex Factors
• ISSN: 0895-8696; 1559-1166
• DOI: 10.1007/s12031-020-01488-w

Reports of spectrum of clinical manifestations in PMP22 gene–associated neuropathies (duplication/mutations) are scarce. To identify the frequency of PMP22 gene variations and establish their genotype-phenotype correlation. Patients with suspected genetic demyelinating neuropathy ( n  = 128) underwent evaluation for copy number variations and point mutations in PMP22 gene by multiplex ligation-dependent probe amplification (MLPA) and direct sequencing respectively. Of these, only 27 patients (M:F:19:8) from 18 families had PMP22 gene–associated neuropathy; they were subsequently analyzed for genotype-phenotype correlation. Twenty-five patients had PMP22 duplication while two patients had PMP22 missense mutations (p.A114V and p.L80P). Age at onset of neuropathy ranged from infancy to 63 years and symptom duration ranged from 2 to 32 years. Cranial nerve dysfunction in the form of ptosis, ophthalmoplegia, bifacial weakness, and sensorineural hearing loss was observed in addition to a number of systemic features. Three patients were asymptomatic. All except one patient were ambulant. Velocity of median nerve and amplitude of evoked motor responses from common peroneal nerve were significantly reduced in male patients. There was significantly worse disability in the late-onset group as compared with the early-onset group. Otherwise, the mean age at onset, frequency of skeletal deformities, patterns of motor weakness, muscle stretch reflexes, sensory impairment, disability rating scales, and electrophysiological parameters were comparable irrespective of gender, onset age, family history and ulnar nerve conduction velocities. The relatively low frequency of PMP22 duplication in the present cohort warrants a more comprehensive search to establish the genetic etiology. Further research into the role of other genetic variants as well as modifier genes and their effect on phenotypic heterogeneity is indicated.